Tsuyoshi Miyamura was appointed as President & CEO and Representative Director on Jun. 24, 2025.
Based on its management philosophy of "contributing to people's health through the development of innovative biotechnologies such as genetic therapies," the Takara Bio Group is developing its business worldwide in the fields of support for life science research and support for health and medical-related industries, while advancing the development of proprietary fundamental technologies with genetic engineering and cell engineering technologies as its core competencies.
The environment surrounding us continues to be challenging due to the slump in the life science research market worldwide. Within this environment, we have invested and continued to take on challenges in the 3 businesses of reagents and equipment, CDMO and genetic medicine under the Medium-Term Management Plan 2026. In 2025, as we acquired Curio Bioscience and ViSpot, and decided to redesign the regulatory strategy for NY-ESO-1・siTCR® Gene Therapy (TBI-1301) to adapt the environment change flexibly, we believe that we have established a foundation for growth. We intend to monetize these with a sense of speed and link them to the next medium-term management plan that will begin in FY2027.
We will also tackle various social issues related to sustainability, including health, and take on the challenge of promoting sustainability management with the aim of achieving both a sustainable society and the sustainable growth of our group. The Takara Bio Group will continue to create new value through aggressive business activities, aiming for sustainable growth, and contributing to society as a global platform that is responsible for the infrastructure of the life science industry.
We deeply appreciate your ongoing support.
Jun. 2025
Tsuyoshi Miyamura
President ＆ CEO
